New Jersey Association of Blood Bank Professionals has partnered with Class Action Capital, the premiere provider of class action settlement claim management and monetization to the global corporate community. Growing from 30 clients in 2012 to over 5,000 clients to date, Class Action Capital’s value is understanding the entire class action landscape and bringing to your attention the settlements that will be in your best financial interest.

Class Action Capital is successfully working with a very large number of hospitals, healthcare facilities and state hospital associations across the country helping to recover meaningful refunds on their behalf from a number of class action settlements. Many companies do not have the time, resources or relevant data available in order to file a settlement claim. Class Action Capital will work with you in order to submit fully comprehensive claim recovery while minimizing your time, internal resources and the risk of mistake if you were to take on claims management on your own.

Below, please find information on the Blood Reagents Direct Purchaser Antitrust Settlement which we believe is applicable to your organization.

The plaintiffs claim that the defendants’ alleged conduct violated federal antitrust law which resulted in individuals and other entities paying more for Traditional Blood Reagents than they normally should have.

Blood Reagents are products which test, match, detect, screen, diagnose and/ or otherwise identify certain properties of the cell and serum components of human blood. Traditional Blood Reagents are primarily used to test blood manually in test tubes. In contrast, proprietary blood reagents are primarily used to test blood in automated and/ or semi-automated platforms.

Your company is likely eligible if you purchased Traditional Blood Reagents in the United States directly from either of the defendants during the period of November 4, 2000 through October 19, 2015. Even if you meet the above requirements, you are not a member of the class if you are a federal government entity, the defendant, defendant’s parent, subsidiary or affiliated company.

The defendants are Immucor, Inc (Immocor) and Ortho-Clinical Diagnostics, Inc. (Ortho) and have settled for $41.5 million. The claim filing deadline has not been set.

For the purpose of this settlement, the definition of Traditional Blood Reagents does not include Ortho’s 0.8% red blood cell reagents and the certified class includes purchases of only Traditional Blood Reagents; the certified class does not include purchases of proprietary blood reagents and/or Ortho’s 0.8% red blood cell reagents.